Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New Brunswick, New Jersey 08901


The purpose of this study is to determine the safety and preliminary effectiveness of ixabepilone plus lapatinib with and without capecitabine in the treatment of human epidermal growth factor receptor 2 (HER2)-positive or metastatic breast cancer.


Inclusion Criteria: - Females aged 18 years or older with histologic or cytologic diagnosis of adenocarcinoma originating in the breast - Radiologic or pathologic evidence that the cancer is metastatic or locally advanced (a T4 tumor and stage IIIB/IIIC disease) and not curable by local measures, such as radiation or surgery - Positive status for human epidermal growth factor receptor 2 - Measurable disease as per Response Evaluation Criteria In Solid Tumors guidelines - Karnofsky performance status of 70 to 100 - Life expectancy of at least 3 months Exclusion Criteria: - Prior radiation must not have included 30% or more of major bone-marrow containing areas, such as the pelvis and lumbar spine - Common Terminology Criteria Grade 2 or greater neuropathy - Inadequate hematologic, hepatic, or renal function - Known prior severe hypersensitivity reactions to agents containing Cremophor® EL or known hypersensitivity or prior intolerance to fluoropyrimidine - Known or suspected dihydropyrimidine dehydrogenase deficiency - More than 3 prior chemotherapy regimens in the metastatic setting - Prior treatment with an epothilone or lapatinib; prior treatment with capecitabine within the past 6 months



Primary Contact:

Study Director
Bristol-Myers Squibb
Bristol-Myers Squibb

Backup Contact:


Location Contact:

New Brunswick, New Jersey 08901
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.